Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: INDV

Indivior Pharmaceuticals Inc

Healthcare | Drug Manufacturers - Specialty & Generic

No licensed closing price on file for INDV. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$2.79

Indivior Pharmaceuticals Inc (NASDAQ: INDV) is a specialty and generic drug manufacturer. Figures from SEC EDGAR; updated 2026-10-21 05:39 UTC.

What Indivior Pharmaceuticals Inc does

Indivior is a pharmaceutical company specializing in long-acting injectable medications for opioid use disorder, with its primary market in the U.S. The company's core products are SUBLOCADE, a monthly buprenorphine injection approved in 2017, and SUBOXONE Film, a sublingual film medication. Indivior operates primarily in the U.S. but also distributes products in Canada, Australia, France, and Germany, with the U.S. accounting for the majority of net revenues.

Summarized from Indivior Pharmaceuticals Inc’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$2.79
Return on equity-214.29%

Revenue, margins & earnings

FY2022: net loss $44M on revenue $901M$901MFY2022FY2023: net loss $126M on revenue $1.09B$1.09BFY2023FY2024 Taxes & interest: $31MFY2024 Operating expenses: $919MFY2024 Cost of revenue: $231M$1.19BFY2024FY2025 Net income: $210MFY2025 Taxes & interest: $52MFY2025 Operating expenses: $732MFY2025 Cost of revenue: $245M$1.24BFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-27
  • 2026-08-27Chief Accounting OfficerPurchase1,500$53.5K
  • 2026-08-05Chief Accounting OfficerPurchase1,500$54.4K
  • 2026-07-13Chief Scientific OfficerSale-18,586$764.6K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Indivior Pharmaceuticals Inc do?

Indivior is a pharmaceutical company specializing in long-acting injectable medications for opioid use disorder, with its primary market in the U.S.

When did INDV last file with the SEC?

Indivior Pharmaceuticals Inc's most recent SEC filing on record is a 8-K filed 2026-05-15. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 05:39 UTC. This page is also available as JSON at /api/data?ticker=INDV and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for INDV and 5,000+ tickers.

Create a free account — keep INDV
For your agent
GET /api/data?ticker=INDV

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt